MRNA therapy takes on rare hormone disorder
NCT ID NCT07197450
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This early-stage trial tests an experimental mRNA drug called XH02 in 6 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone (PTH). The drug aims to temporarily replace PTH after a single intravenous dose. Researchers will monitor safety and measure hormone and mineral levels in the blood. This is a first step to see if the approach is safe and works as intended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.